| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| R&D Expense | $7.0M | — | -33.3% |
| SG&A Expense | $4.3M | — | -14.3% |
| Operating Income | -$11.3M | — | -120.6% |
| Net Income | -$9.0M | — | -116.0% |
| EPS (Basic) | -$0.16 | — | -116.0% |
| EPS (Diluted) | -$0.16 | — | -116.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $30.1M | +43.3% | -69.4% |
| Current Assets | $123.0M | -7.2% | -21.0% |
| Total Assets | $132.9M | -7.1% | -24.6% |
| Current Liabilities | $14.5M | -7.6% | -13.7% |
| Total Liabilities | $28.6M | -7.1% | -17.6% |
| Stockholders' Equity | $104.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$10.2M | — | -119.2% |
| Investing Cash Flow | $19.5M | — | +128.2% |
| Financing Cash Flow | -$185K | — | -678.1% |
| -26.3% |